406 related articles for article (PubMed ID: 37372349)
41. Immune checkpoint inhibitor therapy in neoadjuvant and adjuvant treatment for cancer: A paradigm shift in the treatment of resectable gastrointestinal cancer 3)A paradigm shift in the treatment of colorectal cancer.
Oshima K; Yamazaki K
Int J Clin Oncol; 2023 Nov; 28(11):1442-1450. PubMed ID: 37668816
[TBL] [Abstract][Full Text] [Related]
42. High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer.
Möller K; Blessin NC; Höflmayer D; Büscheck F; Luebke AM; Kluth M; Hube-Magg C; Zalewski K; Hinsch A; Neipp M; Mofid H; Lárusson H; Daniels T; Isbert C; Coerper S; Ditterich D; Rupprecht H; Goetz A; Bernreuther C; Sauter G; Uhlig R; Wilczak W; Simon R; Steurer S; Minner S; Burandt E; Krech T; Perez D; Izbicki JR; Clauditz TS; Marx AH
Acta Oncol; 2021 Sep; 60(9):1210-1217. PubMed ID: 34092167
[TBL] [Abstract][Full Text] [Related]
43. Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status.
Cohen R; Hain E; Buhard O; Guilloux A; Bardier A; Kaci R; Bertheau P; Renaud F; Bibeau F; Fléjou JF; André T; Svrcek M; Duval A
JAMA Oncol; 2019 Apr; 5(4):551-555. PubMed ID: 30452494
[TBL] [Abstract][Full Text] [Related]
44. Opportunities for immunotherapy in microsatellite instable colorectal cancer.
Westdorp H; Fennemann FL; Weren RD; Bisseling TM; Ligtenberg MJ; Figdor CG; Schreibelt G; Hoogerbrugge N; Wimmers F; de Vries IJ
Cancer Immunol Immunother; 2016 Oct; 65(10):1249-59. PubMed ID: 27060000
[TBL] [Abstract][Full Text] [Related]
45. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
[TBL] [Abstract][Full Text] [Related]
46. Single-cell sequencing reveals the immune microenvironment landscape related to anti-PD-1 resistance in metastatic colorectal cancer with high microsatellite instability.
Wu T; Zhang X; Liu X; Cai X; Shen T; Pan D; Liang R; Ding R; Hu R; Dong J; Li F; Li J; Xie L; Wang C; Geng S; Yang Z; Xing L; Li Y
BMC Med; 2023 Apr; 21(1):161. PubMed ID: 37106440
[TBL] [Abstract][Full Text] [Related]
47. Neoadjuvant Immunotherapy in Microsatellite-Instability High Nonmetastatic Colorectal Cancer: A Single-institute Experience and Review of the Literature.
Kinney RE; Khalil M
Clin Colorectal Cancer; 2021 Jun; 20(2):e109-e112. PubMed ID: 33722513
[No Abstract] [Full Text] [Related]
48. Lynch syndrome-associated epithelial ovarian cancer and its immunological profile.
Rasmussen M; Lim K; Rambech E; Andersen MH; Svane IM; Andersen O; Jensen LH; Nilbert M; Therkildsen C
Gynecol Oncol; 2021 Sep; 162(3):686-693. PubMed ID: 34275654
[TBL] [Abstract][Full Text] [Related]
49. Differences in histological features and PD-L1 expression between sporadic microsatellite instability and Lynch-syndrome-associated disease in Japanese patients with colorectal cancer.
Yamada R; Yamaguchi T; Iijima T; Wakaume R; Takao M; Koizumi K; Hishima T; Horiguchi SI
Int J Clin Oncol; 2018 Jun; 23(3):504-513. PubMed ID: 29327160
[TBL] [Abstract][Full Text] [Related]
50. Immunotherapy for Microsatellite Stable Colorectal Cancers: Challenges and Novel Therapeutic Avenues.
Sahin IH; Ciombor KK; Diaz LA; Yu J; Kim R
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-12. PubMed ID: 35658496
[TBL] [Abstract][Full Text] [Related]
51. The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors.
Corti F; Lonardi S; Intini R; Salati M; Fenocchio E; Belli C; Borelli B; Brambilla M; Prete AA; Quarà V; Antista M; Fassan M; Morano F; Spallanzani A; Ambrosini M; Curigliano G; de Braud F; Zagonel V; Fucà G; Pietrantonio F
Eur J Cancer; 2021 Jun; 150():155-167. PubMed ID: 33901794
[TBL] [Abstract][Full Text] [Related]
52. [Immunotherapy of Colorectal and Anal Carcinoma].
Tomášek J; Kiss I
Klin Onkol; 2017; 30(Supplementum3):62-65. PubMed ID: 29239195
[TBL] [Abstract][Full Text] [Related]
53. Microsatellite instability and mismatch repair protein expressions in lymphocyte-predominant breast cancer.
Horimoto Y; Thinzar Hlaing M; Saeki H; Kitano S; Nakai K; Sasaki R; Kurisaki-Arakawa A; Arakawa A; Otsuji N; Matsuoka S; Tokuda E; Arai M; Saito M
Cancer Sci; 2020 Jul; 111(7):2647-2654. PubMed ID: 32449246
[TBL] [Abstract][Full Text] [Related]
54. Microsatellite Instability as a Predictor of Outcomes in Colorectal Cancer in the Era of Immune-Checkpoint Inhibitors.
Lengyel CG
Curr Drug Targets; 2021; 22(9):968-976. PubMed ID: 33970843
[TBL] [Abstract][Full Text] [Related]
55. [Going beyond microsatellite instability for immunotherapy in metastatic colorectal cancer: Consensus molecular subtypes and tumor mutational burden].
Cohen R; Heran M; Pudlarz T; Hilmi M; Tournigand C; André T; Rousseau B
Bull Cancer; 2019 Feb; 106(2):151-161. PubMed ID: 30638897
[TBL] [Abstract][Full Text] [Related]
56. Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update.
Boukouris AE; Theochari M; Stefanou D; Papalambros A; Felekouras E; Gogas H; Ziogas DC
Crit Rev Oncol Hematol; 2022 May; 173():103663. PubMed ID: 35351582
[TBL] [Abstract][Full Text] [Related]
57. Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancer.
Li J; Wu C; Hu H; Qin G; Wu X; Bai F; Zhang J; Cai Y; Huang Y; Wang C; Yang J; Luan Y; Jiang Z; Ling J; Wu Z; Chen Y; Xie Z; Deng Y
Cancer Cell; 2023 Jun; 41(6):1152-1169.e7. PubMed ID: 37172580
[TBL] [Abstract][Full Text] [Related]
58. Current Microsatellite Instability Testing in Management of Colorectal Cancer.
Sun BL
Clin Colorectal Cancer; 2021 Mar; 20(1):e12-e20. PubMed ID: 32888812
[TBL] [Abstract][Full Text] [Related]
59. Clinical significance of microsatellite instability in colorectal cancer.
Kloor M; Staffa L; Ahadova A; von Knebel Doeberitz M
Langenbecks Arch Surg; 2014 Jan; 399(1):23-31. PubMed ID: 24048684
[TBL] [Abstract][Full Text] [Related]
60. Combined Microsatellite Instability and Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST) Might Be a More Promising Immune Biomarker in Colorectal Cancer.
Chen MH; Chang SC; Lin PC; Yang SH; Lin CC; Lan YT; Lin HH; Lin CH; Lai JI; Liang WY; Lu ML; Yang MH; Chao Y
Oncologist; 2019 Dec; 24(12):1534-1542. PubMed ID: 31292272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
